TransMedics Group, Inc. (TMDX)

USD 60.88

(-7.34%)

Market Cap (In USD)

2.04 Billion

Revenue (In USD)

241.62 Million

Net Income (In USD)

-25.02 Million

Avg. Volume

811.66 Thousand

Currency
USD
Country
Healthcare
Open
-
Prev. Close
-
Day Range
-
Year Range
60.395-177.37
PE
-
EPS
-
Beta Value
2.071
ISIN
US89377M1099
CUSIP
89377M109
CIK
1756262
Shares
-
Earnings Annoncement
-

Company Profile

Sector
Healthcare
Industry
Medical - Devices
CEO
Dr. Waleed H. Hassanein M.D.
Employee Count
-
Website
https://www.transmedics.com
Ipo Date
2019-05-02
Details
TransMedics Group, Inc., a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body. Its Organ Care System includes OCS LUNG for the preservation of standard criteria donor lungs for double-lung transplantation; OCS Heart, a technology for extracorporeal perfusion and preservation of donor hearts; and OCS Liver for the preservation of donor livers. The company was founded in 1998 and is headquartered in Andover, Massachusetts.